A Historic Opportunity to Advance PKD Research
The bipartisan PKD Cures Act (H.R. 9169) is the first piece of federal legislation focused exclusively on advancing research for polycystic kidney disease (PKD). Introduced in June 2026 by Representatives Debbie Wasserman Schultz (D-FL), Carol Miller (R-WV), Emanuel Cleaver (D-MO), and Don Bacon (R-NE), the legislation represents an important milestone for the PKD community.
If enacted, the bill would strengthen the National Institutes of Health’s (NIH) commitment to PKD research by expanding research efforts, improving collaboration across the scientific community, and establishing a long-term federal research roadmap.
What Would the PKD Cures Act Do?
The legislation would direct NIH to:
- Expand research on PKD and disease progression
- Advance clinical trials and innovative research approaches
- Improve collaboration across the PKD research community
- Develop a long-term strategy to guide future federal research priorities
Together, these efforts would help accelerate scientific discovery and lay the foundation for better treatments, and ultimately, a cure.
Why It Matters
Federal investment has played a critical role in nearly every major breakthrough in PKD research. The PKD Cures Act builds on that progress by creating a coordinated strategy to ensure researchers have the tools, partnerships, and long-term direction needed to continue advancing the field.
Learn More
- Read the PKD Foundation’s announcement
- Read the congressional sponsors’ press release
- Read the full bill text
Take Action
Congress needs to hear from the PKD community.
Ask your Representative to support the PKD Cures Act and help advance the first-ever federal legislation dedicated exclusively to PKD research.